Could an old drug save your sight? disulfiram trial targets vision loss
NCT ID NCT05626920
First seen May 12, 2026 · Last updated Jun 20, 2026 · Updated 8 times
Summary
This study tests whether disulfiram, a drug already approved for alcohol dependence, can improve vision in people with inherited retinal degeneration. The drug aims to block a harmful signaling pathway in the retina that worsens vision loss. Thirty adults with the condition will receive both disulfiram and a placebo in a crossover design to compare changes in retinal sensitivity and visual acuity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DYSTROPHY PRIMARILY INVOLVING SENSORY RETINA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Washington-South Lake Union Retina Center
RECRUITINGSeattle, Washington, 98109, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Disulfiram (250 mg oral tablet)
What this could lead to
If it works, this could point toward a treatment to slow vision loss and improve remaining sight in people with inherited retinal diseases.
What could go wrong
This is an early Phase 1/2 trial with only 30 participants, so results may not apply broadly. Disulfiram can cause side effects like drowsiness or liver issues, and the benefit may be small or absent.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.